Inhibitor

(redirected from DPP-4 inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Legal.

inhibitor

[in′hib·əd·ər]
(aerospace engineering)
A substance bonded, taped, or dip-dried onto a solid propellant to restrict the burning surface and to give direction to the burning process.
(chemistry)
A substance which is capable of stopping or retarding a chemical reaction; to be technically useful, it must be effective in low concentration.

Inhibitor

 

a circuit having m + n inputs and a single output, at which a signal can appear only when there are no signals on the m inputs (inhibiting). The other n inputs (principal) form one of the two logic connections, “AND” or “OR.” Inhibitors are used extensively in computers. They are very often understood to be a circuit having a single principal input and a single inhibiting input. A signal appears at the output of such a circuit when a signal is present on the principal input but there is none on the inhibiting input. Such an inhibitor is called an anticoincidence gate; its conventional representation is given in Figure 1.

Figure 1. Block diagram of an anticoincidence gate (inhibitor) with m — 1 and n 1:(A) principal input, (Q) inhibiting input, (Ga) anticoincidence gate

inhibitor

A substance added to paint to retard drying, skinning, mildew growth, etc. Also see corrosion inhibitor, inhibiting pigment, drying inhibitor.
References in periodicals archive ?
6) DPP-4 inhibitors were initially found to be associated with fewer cardiovascular events and less hypoglycemia than sulfonylureas, but were subsequently linked to an increased risk of hospitalization for heart failure.
Speaking during the ADA session, study investigator Dr John Buse (University of North Carolina School of Medicine, Chapel Hill) said the DPP-4 inhibitors have been "embraced" by patients and physicians alike.
But further larger studies with more number of patients are needed to evaluate the magnitude of antidiabetic effects of DPP-4 inhibitors.
However, these well conducted studies bring up some consideration about the use of DPP-4 inhibitors in diabetic patients with RA.
The incretin class is composed of GLP-1 agonists and DPP-4 inhibitors.
Compared with the patients who received a DPP-4 inhibitor on top of metformin, those who received a sulfonylurea had an increased risk of both fatal and nonfatal cardiovascular disease (HR, 1.
Astra-Zeneca supported the CREST study and the sulfonylureas versus DPP-4 inhibitor comparison study.
Since launching Januvia (sitagliptin) in 2006 as the first DPP-4 inhibitor in the United States, Merck has continued to collaborate with academic and industry partners on advances in the care of patients with diabetes, and to research and develop innovative treatment options.
Kombiglyze is a combination of saxagliptin (also known as Onglyza), a DPP-4 inhibitor, and metformin immediate-release (metformin IR), a biguanide.
Sitagliptin, which is currently developed by US pharmaceutical firm Merck, is an oral DPP-4 inhibitor with a hypoglycemic mechanism different from the conventional agents.
Use caution in a patient with a history of angioedema with another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with JANUVIA.